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Objectives: This study determined excess mortality and length of hospital stay (LOS) attributable to blood-
stream infection (BSI) caused by third-generation-cephalosporin-resistant Escherichia coli in Europe.
Methods: A prospective parallel matched cohort design was used. Cohort I consisted of patients with third-
generation-cephalosporin-resistant E. coli BSI (REC) and cohort II consisted of patients with third-generation-
cephalosporin-susceptible E. coli BSI (SEC). Patients in both cohorts were matched for LOS before infection
with patients free of the respective BSI. Thirteen European tertiary care centres participated between
July 2007 and June 2008.
Results: Cohort I consisted of 111 REC patients and 204 controls and cohort II consisted of 1110 SEC
patients and 2084 controls. REC patients had a higher mortality at 30 days (adjusted odds ratio¼4.6)
and a higher hospital mortality (adjusted hazard ratio¼5.7) than their controls. LOS was increased by
8 days. For SEC patients, these figures were adjusted odds ratio¼1.9, adjusted hazard ratio¼2.0 and
excess LOS¼3 days. A 2.5 times [95% confidence interval (95% CI) 0.9–6.8] increase in all-cause mortality
at 30 days and a 2.9 times (95% CI 1.2–6.9) increase in mortality during entire hospital stay as well as an
excess LOS of 5 days (95% CI 0.4–10.2) could be attributed to resistance to third-generation cephalosporins
in E. coli BSI.
Conclusions: Morbidity and mortality attributable to third-generation-cephalosporin-resistant E. coli BSI is
significant. If prevailing resistance trends continue, high societal and economic costs can be expected.
Better management of infections caused by resistant E. coli is becoming essential.
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Introduction
Despite growing concerns about increasing antibiotic resistance
there is a lack of information about the impact of antibiotic
resistance on clinical outcomes in infected patients. Studies
attempting to provide this information face considerable chal-
lenges. As most previous studies were carried out in single
centres many have failed to enrol a sufficient number of patients,
leading to imprecision and ambiguity about the true attributable
mortality. To overcome this lack of power, results have been
pooled in meta-analyses,1,2 but this approach inherently suffers
from heterogeneity as a result of data aggregation from
studies with unequal endpoints, different designs and varying
quality. Multicentre studies have the potential to improve pre-
cision and generalizability, but have only been reported
incidentally.3,4
Another challenge in determining the impact of antibiotic
resistance on clinical outcome is how to control for confounding.
Patients infected with resistant pathogens are older, suffer from
more chronic diseases, have more frequently been exposed to
antibiotics and are generally more ill and consequently have
longer hospital exposure than patients infected with susceptible
bacteria.5 – 7 Nevertheless, most studies compared these two
patient groups directly, using multivariate models to adjust for
differences, thereby ignoring the principle that control patients
must be sampled from the population that produced the cases
in order to permit causal inference.8
The present study was designed to improve precision, and
internal and external validity, and provide representative esti-
mates of the morbidity and mortality attributable to
antibiotic-resistant bloodstream infection (BSI) for Europe as a
whole. We chose to investigate Escherichia coli BSI for four
reasons: (i) E. coli is the most frequent cause of BSI in European
hospitals;9 – 11 (ii) compared with other bacteria, antibiotic resist-
ance in E. coli shows the most dramatic increase in Europe and
beyond;12 – 14 (iii) novel antibiotics that could fill the therapeutic
void are unlikely to become available in the near future;15,16
and (iv) little is known about the clinical impact attributable to
antibiotic resistance caused by infections with this species.
This study is the first multicentre study to provide robust esti-
mates of excess 30 day mortality, hospital mortality and hospital
stay attributable to third-generation-cephalosporin-resistant
E. coli (REC) BSI for tertiary care centres in Europe.
Methods
Setting
Thirteen tertiary care centres (WHO definition17) from as many European
countries were selected from hospitals of the European Antimicrobial
Resistance Surveillance System (EARSS).14 They had representative
levels of resistance for their countries. All were served by microbiological
laboratories with good diagnostic practice, according to the results of the
external quality assessment exercise carried out annually by EARSS.
Study design
A prospective parallel matched cohort design was chosen. The first
cohort consisted of patients with third-generation-cephalosporin-
resistant E. coli BSI (REC cohort), and the second cohort consisted of
patients with third-generation-cephalosporin-susceptible E. coli (SEC)
BSI (SEC cohort). Any episode of REC or SEC BSI in an adult patient
(≥18 years) was identified by daily laboratory liaison. Day of enrolment
was defined as the date blood cultures were taken. To improve the
power of this study each identified patient was not matched to one,
but to two controls free of E. coli BSI, based on length of hospital stay
(LOS) (+3 days) before enrolment. If more than two patients were eligible
as controls, the patients closest to the exposed patient in the ward reg-
istry were selected.
Blood cultures were taken on clinical indication and all hospital
patients with blood cultures positive for E. coli, irrespective of antibiotic
resistance, were included as exposed patients. Third-generation cepha-
losporin resistance was determined using EARSS consensus protocols.18
Training of on-site investigators and data collection
For each hospital a dedicated on-site investigator was recruited. During
two workshops, they were trained in standardized patient enrolment
and data collection, using anonymized patient records provided by one
of the co-authors (P. G. D.). Patients were enrolled for 12 months
between July 2007 and June 2008. Anonymized data were recorded
using a web-based and password-protected data submission tool
hosted by the Netherlands National Institute of Public Health and the
Environment. Built-in data checks secured data validity. To further
ensure uniform application of criteria and definitions, one co-author
(M. E. A. de K.) provided continuous helpdesk support. Data sources
were patient records, the electronic hospital information system, the lab-
oratory information system and nursing notes. Post-discharge surveil-
lance to determine survival 30 days after enrolment was carried out by
telephone contact with patients or their general practitioner.
Pre-enrolment data recorded consisted of patient referral history
(long-term care facility, nursing home or other hospital admission), fre-
quent hospital exposure, defined as two or more hospital admissions in
the previous 12 months, current admission diagnosis, type of admission
(emergency or elective), surgery and presence of co-morbidities from the
Charlson co-morbidity index (CCI).19 On enrolment, the presence of
indwelling devices (tracheal tube, central venous catheter, arterial vascu-
lar access, peripheral vascular access, urinary catheter, tracheostomy,
nasogastric tube, wound drainage tube) was recorded and the anatom-
ical origin of the BSI (in the case of secondary BSI), the susceptibility
profile of the causative pathogen and co-infections were ascertained.
Main outcomes were mortality 30 days after enrolment, mortality
during hospital stay and LOS after enrolment.
This study complied with the Dutch patient confidentiality regulations
and ethical standards20 and was approved by local institutional ethics
committees.
Statistical analysis
Statistical analyses were performed using SAS 9.1 and R 2.8.1. Univariate
comparisons of patients with E. coli BSI (either REC or SEC) and the unex-
posed controls were performed using Cochran’s Q statistic for categorical
variables and Friedman’s ranks sum test for continuous variables.
Analyses of outcomes (30 day mortality, hospital mortality and LOS
after enrolment) were performed separately for the REC and SEC
cohorts. Variables were selected for multivariate analysis if they
changed the effect estimate in bivariate regression by .5%. Collinearity
was assessed by generating a correlation coefficient matrix. A robust
sandwich covariance matrix estimator was used to account for the
matched design. The effect attributable to third-generation cephalos-
porin resistance was determined by the ratio of the adjusted effect
measures for REC BSI and SEC BSI from the parallel cohorts, and the
95% confidence intervals (95% CIs) were determined as described by
Altman et al.21
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Thirty day mortality and hospital mortality
The effect of E. coli BSI on mortality was determined by logistic regression
for 30 day mortality (SAS command ‘genmod’) and by Fine and Gray’s
extended Cox’s regression22,23 for competing events for hospital mor-
tality (SAS command ‘bphreg’). Model fit for logistic regression was
assessed by the Hosmer–Lemeshow test. Cumulative incidence graphs
were created using a cause-specific hazard model where both discharge
alive and hospital mortality were included as competing endpoints (R
package ‘cmprsk’, command ‘cuminc’).24,25
LOS after enrolment
A generalized linear model (GLM) with gamma distribution and loglink
function for positively skewed data was used to determine the impact
of E. coli BSI on LOS after enrolment (SAS command ‘genmod’).26,27
Excess LOS was calculated by comparing the mean outcomes predicted
by the multivariate model for all patients in each group; 95% CIs for
the difference in LOS in days were obtained by parametric bootstrapping.
Data heterogeneity
To test for group effects at hospital level, multilevel models for hierarch-
ical data were used for logistic regression and the GLMs. Stratified ana-
lyses were used for the Fine and Gray model.
Results
During the study period, 1328 episodes of E. coli BSI were
reported, of which 129 (10%) isolates showed resistance to third-
generation cephalosporins (Table 1). For 107 (8%) patients with
BSI no appropriate match with equal pre-enrolment time of
admission +3 days could be identified. For 160 (12%) exposed
patients only a single control could be matched. Hence the ana-
lyses were based on 111 patients with REC BSI, 1110 patients
with SEC BSI, matched with 204 and 2084 controls, respectively.
The 107 excluded exposed patients had a longer period between
admission and enrolment than the included patients, other clini-
cal characteristics were comparable. Hospital stay after enrol-
ment was longer as well, while 30 day (x2 test, P¼0.86) and
hospital (x2, P¼0.28) mortality were indistinguishable from the
included exposed patients.
For the 3509 patients included in the analysis, the time from
admission to enrolment was longer in the REC cohort than in the
SEC cohort. Crucial differences existed between the patients in
the two cohorts, which were independent of the exposure
status of the patients. In the REC cohort, exposed patients as
well as controls more often had an elective admission, more fre-
quently received antibiotics before enrolment, had more surgery,
suffered more frequently from cancer/leukaemia, more often
had indwelling devices (such as central venous catheter,
urinary catheter or wound drainage tubes) and their CCI was
higher than for the patients in the SEC cohort. Similarly, some
consistent differences between exposed and control patients
could be identified in both cohorts. Patients with BSI in both
cohorts more often had previous hospital admissions, genitourin-
ary disorders or infections on admission, suffered more often
from peripheral vascular diseases, diabetes with or without
end-organ damage, cancer/leukaemia or dementia and more
often had a central venous catheter or urinary catheter than
the controls (Table 2).
Thirty day mortality
In the REC cohort, 34 of the 105 (32%) patients with a resistant
E. coli BSI died within 30 days after enrolment, in contrast to only
11 of the 196 (6%) control patients. Almost all deaths occurred
in hospital. Only one exposed patient died at home and only one
control patient died in a nursing home. In the SEC cohort, 180 of
the 1067 (17%) patients with a susceptible E. coli BSI died within
30 days of acquiring the infection, whereas mortality among
controls was 137/1984 (7%). Again, most patients died in hospi-
tal, only 11 (6%) of the exposed and 24 (18%) of the controls
died after discharge. Table 3 summarizes the results from the
univariate and multivariate models. Multilevel analysis showed
that group effects at hospital level did not change the coeffi-
cients for E. coli BSI exposure and therefore the presented
results are based on regular logistic regression. After adjusting
for potential confounders, REC BSI was associated with 30 day
mortality with an adjusted odds ratio of 4.6 (95% CI 1.7–12.3)
compared with controls without E. coli BSI. In the SEC cohort,
the adjusted odds ratio was 1.9 (95% CI 1.4–2.5).
Comparison of excess 30 day mortality between the two
cohorts showed that mortality associated with REC BSI was 2.5
(95% CI 0.9–6.8) times higher than for patients infected with
susceptible strains.
Hospital mortality
Thirty-nine of 109 (36%) patients with REC BSI died while in hos-
pital, whereas 11 of 204 (5%) control patients died in hospital.
The median time from enrolment to death was 3 days for the
patients exposed to REC BSI [interquartile range (IQR) 1–12],
while median time to death was 9 days (IQR 4–17) among con-
trols. In the SEC cohort, hospital mortality was 190/1101 (17%)
among patients exposed to SEC BSI and 141/2070 (7%) among
Table 1. Activity data of participating hospitals from July 2007 to
June 2008
Hospital
number Country Beds Admissions Bed-days
BSI/
controls
National
REC%a
H1 Austria 2137 99761 657268 84/171 7
H2 Belgium 856 26337 290790 64/128 4
H3 Croatia 1724 63804 479528 78/154 4
H4 England 1210 104680 292030 216/428 7
H5 Germany 1234 56193 391258 60/113 5
H6 Greece 949 44214 293632 84/112 10
H7 Ireland 819 22418 238166 124/244 6
H8 Italy 912 55600 292150 106/210 16
H9 Latvia 1029 46343 307006 17/34 9
H10 Malta 835 48504 252488 92/164 21
H11 Romania 1109 72739 427666 23/39 24
H12 Scotland 877 53276 255215 172/333 7
H13 Slovenia 2344 83161 614353 208/407 4
Overall 13 16035 777030 4791550 1328/2537 12
BSI, number of first episodes of E. coli bloodstream infection.
aProportion of REC according to EARSS 2008.14
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Table 2. Characteristics of patients with E. coli BSI and matched controls, separately for the REC cohort and the SEC cohort
REC cohort SEC cohort
BSI (%) n controls (%) n P value BSI (%) n controls (%) n P value
Female gender 58 (52) 111 110 (54) 204 0.97 622 (56) 1110 1071 (51) 2084 0.05
Agea (years) 73 (60–83) 111 66 (50–79) 204 0.42 73 (60–81) 1110 68 (52–79) 2084 ,0.01
Transfer from another institution 30 (31) 98 17 (9) 179 ,0.01 137 (14) 960 158 (9) 1786 ,0.01
More than two hospital stays in previous year 41 (42) 98 51 (28) 179 ,0.01 232 (24) 960 359 (20) 1786 ,0.01
Emergency admission 68 (62) 110 120 (59) 204 0.62 932 (84) 1110 1454 (70) 2082 ,0.01
Antibiotic therapy before enrolment 54 (49) 111 103 (50) 204 0.23 396 (36) 1110 883 (42) 2084 ,0.01
Surgery before enrolment 26 (23) 111 40 (20) 204 0.45 145 (13) 1110 282 (14) 2083 0.08
LOS before enrolmenta (days) 5 (0–14) 111 4 (1–14) 204 0.43 0 (0–3) 1110 1 (0–3) 2084 ,0.01
Admission diagnosis
cardiovascular disease 7 (6) 111 25 (12) 204 0.25 76 (7) 1110 321 (15) 2084 ,0.01
connective tissue disease 0 111 0 204 — 2 (0) 1110 20 (1) 2084 0.11
dermatological causes 2 (2) 111 4 (2) 204 1.00 6 (1) 1110 23 (1) 2084 0.25
endocrine/metabolic causes 1 (1) 111 9 (4) 204 ,0.05 17 (2) 1110 88 (4) 2084 ,0.01
gastrointestinal causes 16 (14) 111 36 (18) 204 0.64 231 (21) 1110 428 (21) 2084 0.77
genitourinary causes 23 (21) 111 14 (7) 204 ,0.01 221 (20) 1110 201 (10) 2084 ,0.01
gynaecological causes 0 (0) 111 2 (1) 204 0.14 14 (1) 1110 33 (2) 2084 0.36
haematological causes 9 (8) 111 19 (9) 204 0.90 27 (2) 1110 66 (3) 2084 ,0.05
infectious disease 17 (15) 111 13 (6) 204 ,0.01 287 (26) 1110 179 (9) 2084 ,0.01
neurological causes 2 (2) 111 9 (4) 204 0.64 27 (2) 1110 95 (5) 2084 ,0.01
oncological causes 15 (14) 111 33 (16) 204 0.77 82 (7) 1110 186 (9) 2084 0.09
orthopaedic causes 6 (5) 111 10 (5) 204 1.00 21 (2) 1110 45 (2) 2084 0.08
pulmonary causes 7 (6) 111 20 (10) 204 0.71 43 (4) 1110 226 (11) 2084 ,0.01
trauma 2 (2) 111 2 (1) 204 1.00 20 (2) 1110 37 (2) 2084 0.54
undetermined 4 (4) 111 8 (4) 204 0.55 36 (3) 1110 136 (7) 2084 ,0.01
CCI
Charlson scorea 3 (1–4) 111 2 (1–3) 204 ,0.01 2 (1–3) 1110 2 (0–3) 2082 ,0.01
myocardial infarct 9 (8) 111 11 (5) 204 0.70 101 (9) 1110 196 (9) 2083 0.88
congestive heart failure 18 (16) 111 25 (12) 204 0.36 150 (14) 1110 305 (15) 2082 0.45
cerebrovascular disease 12 (11) 111 24 (12) 204 0.15 119 (11) 1110 203 (10) 2083 0.12
chronic pulmonary disease 12 (11) 111 25 (12) 204 0.86 120 (11) 1110 310 (15) 2083 ,0.05
mild liver disease 2 (2) 111 6 (3) 204 0.87 49 (4) 1110 53 (3) 2083 ,0.05
severe liver disease 7 (6) 111 7 (3) 204 0.41 53 (5) 1110 72 (3) 2083 0.24
severe renal disease 17 (15) 111 22 (11) 204 0.53 183 (16) 1110 261 (13) 2083 ,0.01
peripheral vascular disease 18 (16) 111 18 (9) 204 0.08 95 (9) 1110 160 (8) 2083 0.51
connective tissue disease 9 (8) 111 11 (5) 204 0.24 101 (9) 1110 196 (9) 2083 0.65
peptic ulcer 3 (3) 111 5 (2) 204 0.42 57 (5) 1110 101 (5) 2083 0.46
diabetes 30 (27) 111 28 (14) 204 ,0.05 232 (21) 1110 365 (18) 2083 ,0.05
diabetes with end-organ damage 15 (14) 111 4 (2) 204 ,0.01 43 (4) 1110 69 (3) 2083 0.27
hemi/paraplegia 1 (1) 111 4 (2) 204 0.45 41 (4) 1110 58 (3) 2083 0.17
cancer/leukaemia 35 (32) 111 56 (27) 204 0.61 242 (22) 1110 425 (20) 2083 0.67
metastatic solid tumour 9 (8) 111 17 (8) 204 0.34 90 (8) 1110 124 (6) 2083 0.15
AIDS 2 (2) 111 0 (0) 204 — 1 (0) 1110 7 (0) 2083 0.61
dementia 10 (9) 111 9 (4) 204 0.35 73 (7) 1110 96 (5) 2083 0.09
Indwelling devices on enrolment
tracheal tube 9 (8) 110 5 (2) 204 ,0.05 56 (5) 1109 51 (2) 2084 ,0.01
central venous catheter 36 (33) 110 36 (18) 203 ,0.01 190 (17) 1109 219 (11) 2079 ,0.01
arterial vascular access 9 (8) 110 9 (4) 204 0.41 82 (7) 1109 75 (4) 2082 ,0.01
peripheral vascular access 83 (76) 109 134 (66) 204 ,0.01 863 (78) 1108 1405 (68) 2070 ,0.01
urinary catheter 52 (48) 111 48 (24) 204 ,0.01 474 (43) 1109 408 (20) 2083 ,0.01
tracheostomy 5 (5) 111 3 (1) 204 ,0.05 14 (1) 1110 16 (1) 2083 0.70
Continued
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controls. SEC BSI patients died after a median of 7 days post-
infection (IQR 1–17), while the control patients died after a
median of 12 days after enrolment (IQR 6–28).
The dynamics of hospital mortality and discharge for both
cohorts is illustrated in Figure 1. In both panels (Figure 1a and b)
the upper two curves show the cumulative discharge rate for
the controls (top curve) and the exposed patients, the lower two
curves show the cumulative incidence of hospital mortality, with
the lowest curve representing mortality of control patients.
Figure 1(a) shows that most patients with REC BSI die relatively
soon after ascertainment of the infection, while the discharge
rate for exposed patients was lower and much more dispersed
Table 2. Continued
REC cohort SEC cohort
BSI (%) n controls (%) n P value BSI (%) n controls (%) n P value
nasogastric tube 16 (14) 111 15 (7) 204 0.09 86 (8) 1108 118 (6) 2083 0.14
wound drainage tube 11 (10) 111 19 (9) 204 0.43 54 (5) 1110 98 (5) 2082 0.99
Characteristics of the BSI
polymicrobial BSI 9 (8) 111 103 (9) 1099
hospital onset of BSI (.48 h) 63 (57) 111 308 (28) 1110
Source
bone/joint 0 111 5 (0) 1110
CNS foci 0 111 0 1110
intervention 1 (1) 111 22 (2) 1110
ear–nose–throat 0 111 1 (0) 1110
intra-abdominal 22 (20) 111 207 (19) 1110
intravascular 2 (2) 111 22 (2) 1110
lower respiratory tract 7 (6) 111 33 (3) 1110
skin/soft-tissue 4 (4) 111 26 (2) 1110
urinary–genital 49 (44) 111 544 (49) 1110
unknown 26 (23) 111 250 (23) 1110
Outcomes
death in hospital 39 (36) 109 11 (5) 204 ,0.01 190 (17) 1101 141 (7) 2070 ,0.01
death within 30 days after enrolment 34 (32) 105 11 (6) 196 ,0.01 180 (17) 1067 137 (7) 1984 ,0.01
LOS after enrolmenta (days) 12 (6–25) 109 6 (3–16) 204 ,0.05 10 (6–17) 1101 7 (4–14) 2071 ,0.01
P values correspond to Cochran’s Q statistic and Friedman’s ranks sum test, whenever appropriate.
aMedian and interquartile range.
Table 3. Impact of REC or SEC BSI on 30 day mortality: univariate and multivariate logistic regression, and comparison of adjusted effect estimates
from both cohorts
Type of analysis n
OR for effect measure
(95% CI) Effect measure; potential confounders in model
REC versus controls
univariate 294 7.2 (3.4–15.2) REC BSI
multivariate 248 4.6 (1.7–12.3) REC BSI; tracheal tube, central venous catheter, urinary catheter, transfer from
another institution, CCI, number of indwelling devices
SEC versus controls
univariate 2961 2.7 (2.2–3.4) SEC BSI
multivariate 2494 1.9 (1.4–2.5) SEC BSI; age, emergency admission, central venous catheter, urinary catheter,
transfer from another institution, number of indwelling devices
REC cohort versus SEC cohort
comparison of adjusted
effect estimates
2.5 (0.9–6.8) third-generation cephalosporin resistance of E. coli BSI
OR, odds ratio.
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than that for controls. Conversely, Figure 1(b) reveals that patients
with SEC BSI were discharged more quickly after ascertainment of
the infection and almost at the same rate as the controls.
The same dynamics are captured by the hazard ratios in Table 4.
Since stratified analysis showed that group effects at hospital level
did not change the coefficients for E. coli BSI exposure, the pre-
sented results are based on the non-stratified Fine and Gray
model. Compared with controls, the adjusted hazard ratio for hos-
pital mortality among patients exposed to REC BSI was 5.7 (95% CI
2.5–13.0), and for patients with SEC BSI 2.0 (95% CI 1.5–2.5).
Comparison of excess hospital mortality in the two cohorts
showed that the adjusted hazard ratio for patients infected with
REC strains was 2.9 (95% CI 1.2–6.9) times higher than the
adjusted hazard ratio for patients who had SEC BSI.
LOS
On average, patients with an E. coli BSI stayed in hospital longer
than control patients. This effect was more pronounced for
patients with REC BSI than for patients with SEC BSI. Patients
with REC BSI stayed in hospital for a median of 12 days (IQR
6–25) after ascertainment of the infection compared with
6 days (IQR 3–16) for the controls. The patients exposed to
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Figure 1. Unadjusted cumulative incidence functions for the competing risks discharge alive and hospital mortality, for patients with and without
E. coli BSI. (a) Patients with REC BSI and their matched controls. (b) Patients with SEC BSI and their matched controls.
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SEC BSI stayed for a median of 10 days (IQR 6–17) as compared
with 7 days (IQR 4–14) for control patients.
Multilevel analysis showed that group effects at hospital level
did not change the coefficients for E. coli BSI exposure and there-
fore the presented results are based on regular GLMs. After taking
into account underlying differences between exposed and control
patients, patients with REC BSI still had a longer hospital stay; they
stayed 1.5 (95% CI 1.2–2.0) times longer than controls, resulting
in an excess LOS of 8 days (95% CI 4–13). Patients with SEC BSI
also stayed longer in hospital, although the adjusted ratio was
1.2 (95% CI 1.1–1.3), resulting in 3 excess days. Comparing the
effects of the REC and SEC cohorts, the excess LOS attributable
to third-generation cephalosporin resistance in E. coli BSI was esti-
mated to be 5 days (95% CI 0.4–10.2) (Table 5).
Discussion
In Europe, the most rapid increase in antibiotic resistance in
E. coli has been seen in the past decade.14 This has been due
mainly to the expansion of extended-spectrum b-lactamase
(ESBL) genes of the CTX type that confer resistance to most third-
Table 5. Impact of a REC or SEC BSI on length of hospital stay after infection: univariate and multivariate analysis (generalized linear model with
gamma distribution and loglink function), and comparison of multivariate effect estimates from both cohorts
Type of analysis n
Ratio of mean LOS for
effect measure
(95% CI)
Extra LOS in days for
effect measure
(95% CI) Effect measure; potential confounders in model
REC versus controls
univariate 311 1.7 (1.3–2.1) 8.4 (4.3–13.0) REC BSI
multivariate 264 1.5 (1.2–2.0) 7.9 (3.5–13.0) REC BSI; antibiotic therapy before enrolment, central venous
catheter, urinary catheter, nasogastric tube, more than two
hospital stays in previous year, transfer from another
institution, diabetes with end-organ damage, CCI, number of
indwelling devices
SEC versus controls
univariate 3154 1.2 (1.1–1.3) 2.8 (1.6–4.0) SEC BSI
multivariate 3116 1.2 (1.1–1.3) 2.9 (1.7–4.0) SEC BSI; antibiotic therapy before enrolment, central venous
catheter, urinary catheter, number of indwelling devices
REC cohort versus SEC cohort
comparison of
adjusted effect
estimates
1.3 (1.0–1.7) 5.0 (0.4–10.2) third-generation cephalosporin resistance of E. coli BSI
Table 4. Impact of REC or SEC BSI on hospital mortality: univariate and multivariate proportional subdistribution hazards regression model of Fine
and Gray, and comparison of adjusted effect estimates from both cohorts
Type of analysis n
HR for effect measure
(95% CI) Effect measure; potential confounders in model
REC versus controls
univariate 315 7.9 (4.0–15.3) REC BSI
multivariate 268 5.7 (2.5–13.0) REC BSI; tracheal tube, central venous catheter, urinary catheter, transfer from
another institution, number of indwelling devices
SEC versus controls
univariate 3193 2.7 (2.2–3.3) SEC BSI
multivariate 2699 2.0 (1.5–2.5) SEC BSI; age, emergency admission, tracheal tube, central venous catheter, arterial
vascular access, urinary catheter, transfer from another institution, CCI, number
of indwelling devices
REC cohort versus SEC cohort
comparison of adjusted
effect estimates
2.9 (1.2–6.9) third-generation cephalosporin resistance of E. coli BSI
HR, hazard ratio.
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generation cephalosporins. In order to assess the impact of this
disquieting trend on the lives of patients and the burden on the
health service, we conducted a prospective, multicentre study to
determine mortality and prolongation of hospital stay attribu-
table to REC in Europe. Patients with REC BSI were 2.5 (95% CI
0.9–6.8) times more likely to die within the first 30 days after
infection and had a 2.9 times (95% CI 1.2–6.9) higher instan-
taneous probability of dying during their hospital stay compared
with patients infected with a susceptible strain. At the same
time, third-generation cephalosporin resistance prolonged the
duration of hospitalization by 5 days (95% CI 0.4–10.2).
We studied three different outcome measures, which allowed
our assessment of the clinical impact of antimicrobial-resistant
E. coli to be more comprehensive than previously reported.
Whilst 30 day mortality is a static measure indicating excess
mortality within the first month, hospital mortality, if analysed
by appropriate time-to-event methods, provides insight into the
temporal dynamics of mortality during the entire hospital stay.
Prolongation of hospital stay served as a surrogate marker for
morbidity as well as an indicator of costs borne by the healthcare
system and society.28
The main strength of our study is that through the parallel
cohort design and matching on LOS before infection we were
able to comprehensively adjust for confounders, including
unmeasured residual confounders. This increased the probability
that the observed effects are attributable to the resistance phe-
notype per se. The CCI was used to further reduce confounding
by differences in health status. As has been shown by others,
the CCI is an adequate predictor of mortality in patients with
BSI.29 More importantly, CCI is independent of acute severity of
disease and thus is not part of the chain of events between
infection and outcome.30
A further strength of our study is that we focused on E. coli,
avoiding non-specific effect estimates arising from studying a
combination of pathogens.31 In this respect, our results can be
compared with two single-centre studies. In one large study no
impact of resistance in E. coli on 30 day mortality was found.32
However, by including variables that are on the causative
pathway such as ‘shock’ and ‘inappropriate therapy’, the true
effect of resistance was likely underestimated.30 Results from
the second, smaller study were consistent with our estimate
for 30 day mortality.33
Adjusting for confounding is important to improve the validity of
the estimate of interest, but it compromises the precision of the
estimate. After controlling for confounding variables, the
estimated effect on 30 day mortality [adjusted odds ratio¼2.5
(95% CI 0.9–6.8, P¼0.08)] was not precise enough to exclude
random error at the conventional threshold for an alpha error of
≤0.05. However, the increases in hospital mortality and LOS associ-
ated with third-generation cephalosporin resistance were signifi-
cant, indicating that chance is not a very likely explanation. Apart
from this limitation there are two possible sources of bias that
need to be considered. First, blood culture frequency varied
between the centres. This could have caused ascertainment bias,
whereby exposed patients were erroneously included as controls,
potentially underestimating the impact of E. coli BSI on clinical
outcome. However, the incidence of BSI is low and therefore the
impact of this bias is likely to be low. Furthermore, sensitivity analy-
sis excluding centres with low blood culturing frequency did not
change overall effect estimates (data not shown). Second,
heterogeneity between participation study centres regarding clini-
cal management of patients or virulence among locally prevalent
E. coli clones could influence the association between antibiotic
resistance and mortality. If this is ignored during the analysis, it
could conceal the true relationship between exposure and
outcome. However, we showed by multilevel analyses that differ-
ences between participating centres did not modify the results.
Moreover, other studies have shown that variation in the phyloge-
netic background of E. coli strains34 was not related to mortality in
patients with BSI. Nevertheless, a small effect due to differences in
healthcare systems can never be ruled out.
Our results are increasingly relevant, because multiresistant
E. coli BSIs impose a growing burden on populations in
Europe and worldwide.12,14,35 Moreover, faecal carriage of
antibiotic-resistant, frequently ESBL-producing, E. coli is increas-
ing in the community36,37 and is associated with a greatly
increased risk of subsequent infection.37 Reservoirs for multiresis-
tant E coli that can spill into the community include nursing
homes38 and food production animals.39 Finally, few options
exist to treat REC infections and new compounds will not
become available in the near future.15 Carbapenems are
suggested for empirical treatment of serious infections involving
REC; however, over the last few years E. coli resistant to third-
generation cephalosporins as well as carbapenems have been
increasingly reported.40
To conclude, we showed that REC BSIs have a considerable
impact on mortality and morbidity in Europe. In conjunction
with the rapid progression of REC in hospitals and the emergence
of these pathogens in the community, high societal and econ-
omic costs can be expected. Control strategies aimed at decreas-
ing the overall biomass of REC, and for that matter all other
third-generation-cephalosporin-resistant Enterobacteriaceae, as
well as additional investments in novel therapeutic approaches,
are urgently needed.
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